Abbott Laboratories (ABT), Monday announced the launch of Libre Assist, a new feature within the Libre app designed to help people with diabetes in the U.S.
The recently launched feature lets users know how the foods they eat affect their glucose levels and provide tips to reduce the glucose impact.
Notably, Libre Assist does not require any additional monthly fees, additional purchases or separate prescription.
Marc Taub, vice president of technical operations for Abbott's diabetes care business, commented, "That's why Abbott built Libre Assist1 - a free, and advanced predictive tool that delivers personalized meal guidance and works with our leading Libre technology to deliver real-time glucose insights."
Currently, ABT is trading at $123.31, down 0.71 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.